IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: A study of 54 cases

Journal of Investigative Dermatology

Volumn 130, Issue 3, 2010, Pages 816-825

  Pham Ledard, Anne ^a   Prochazkova Carlotti, Martina ^a   Laharanne, Elodie ^a   Vergier, Béatrice ^b   Jouary, Thomas ^b   Beylot Barry, Marie ^a   Merlio, Jean Philippe ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Department of Pathology and Tumor Biology ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 4;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CELL TRANSFORMATION; CHROMOSOME 6; CONTROLLED STUDY; CORRELATION ANALYSIS; CUTANEOUS T CELL LYMPHOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE LOCUS; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTOR 4 GENE; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; SEZARY SYNDROME; TRISOMY;

ANTIGENS, CD30; BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 6; DNA BREAKS; FLUORESCENT ANTIBODY TECHNIQUE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON REGULATORY FACTORS; LYMPHOMA, T-CELL, CUTANEOUS; MYCOSIS FUNGOIDES; PLOIDIES; SKIN NEOPLASMS;

EID: 76649135152     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.314     Document Type: Article

References (41)

1. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA et al. (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661
2. Benner MF, Jansen PM, Meijer CJ, Willemze R (2009) Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 161:121-127
3. Beylot-Barry M, Groppi A, Vergier B, Pulford K, Merlio JP (1998) Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. Blood 91:4668-4676
4. Boerma EG, Siebert R, Kluin PM, Baudis M (2009) Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 23:225-234
5. Brustle A, Heink S, Huber M, Rosenplanter C, Stadelmann C, Yu P et al. (2007) The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 8:958-966
6. Chevret E, Prochazkova M, Beylot-Barry M, Merlio JP (2006) A suggested protocol for obtaining high-quality skin metaphases from primary cutaneous T-cell lymphoma. Cancer Genet Cytogenet 167:89-91
7. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA et al. (2007) The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 110:1251-1261
8. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. (2006) Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442
9. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R (1998) Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 92:1150-1159
10. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M et al. (2000) A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95:2084-2092
11. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL et al. (2009) Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 23:574-580
12. Guo F, Sun A, Wang W, He J, Hou J, Zhou P et al. (2009) TRAF1 is involved in the classical NF-[kappa]B activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 46:2441-2448
13. Hernandez-Machin B, de Misa RF, Montenegro T, Rivero JC, Bastida J, Febles C et al. (2009) MUM1 expression does not differentiate primary cutaneous anaplastic large-cell lymphoma and lymphomatoid papulosis. Br J Dermatol 160:713
14. Hirsch B, Hummel M, Bentink S, Fouladi F, Spang R, Zollinger R et al. (2008) CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 172:510-520
15. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B et al. (1997) Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17:226-230
16. Karenko L, Hahtola S, Paivinen S, Karhu R, Syrja S, Kahkonen M et al. (2005) Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res 65:8101-8110
17. Kempf W, Kutzner H, Cozzio A, Sander CA, Pfaltz MC, Muller B et al. (2008) MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol 158:1280-1287
18. Kiessling MK, Klemke CD, Kaminski MM, Galani IE, Krammer PH, Gulow K (2009) Inhibition of constitutively activated nuclear factor-{kappa}B Induces reactive oxygen species-and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 69:2365-2374
19. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A et al. (2007) TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:479-484
20. La Rosa P, Viara E, Hupe P, Pierron G, Liva S, Neuvial P et al. (2006) VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 22:2066-2073
21. Liva S, Hupe P, Neuvial P, Brito I, Viara E, La Rosa P et al. (2006) CAPweb: a bioinformatics CGH array analysis platform. Nucleic Acids Res 34:W477-81
22. Lu R (2008) Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 29:487-492
23. Marty M, Prochazkova M, Laharanne E, Chevret E, Longy M, Jouary T et al. (2008) Primary cutaneous T-cell lymphomas do not show specific NAV3 gene deletion or translocation. J Invest Dermatol 128:2458-2466
24. Michaux L, Wlodarska I, Rack K, Stul M, Criel A, Maerevoet M et al. (2005) Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "un-mutated" B-CLL. Leukemia 19:77-82
25. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A et al. (1997) Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275:540-543
26. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al. (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713-1722
27. Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rouge C et al. (2006) Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q. Br J Cancer 95:1439-1447
28. Remstein ED, Law M, Mollejo M, Piris MA, Kurtin PJ, Dogan A (2008) The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. Leukemia 22:1268-1272
29. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. (2008) IRF4 addiction in multiple myeloma. Nature 454:226-231
30. Shaffer AL, Emre NCT, Romesser PB, Staudt LM (2009) IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res 15:2954-2961
31. Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G et al. (2006) Down-regulating constitutive activation of the NF-{kappa}B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107:2354-2363
32. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC
33. Tamura A, Miura I, Iida S, Yokota S, Horiike S, Nishida K et al. (2001) Interphase detection of immunoglobulin heavy chain gene translocations with specific oncogene loci in 173 patients with B-cell lymphoma. Cancer Genet Cytogenet 129:1-9
34. Verma R, Babu A (1995) Human Chromosomes. Principales and Techniques. 2nd ed. New-York: McGraw-Hill
35. Wasco MJ, Fullen D, Su L, Ma L (2008) The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders. Hum Pathol 39:557-563
36. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785
37. Wright CW, Rumble JM, Duckett CS (2007) CD30 activates both the canonical and alternative NF-{kappa}B pathways in anaplastic large cell lymphoma cells. J Biol Chem 282:10252-10262
38. Yoshida S, Nakazawa N, Iida S, Hayami Y, Sato S, Wakita A et al. (1999) Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia 13:1812-1816
39. Zhao W-L, Liu Y-Y, Zhang Q-L, Wang L, Leboeuf C, Zhang Y-W et al. (2008) PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 111:3867-3871
40. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT et al. (2009) Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458:351-356
41. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M et al. (2007) Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25:4293-4297